Compare ADSE & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADSE | ESPR |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | Ireland | United States |
| Employees | 302 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 858.0M | 814.3M |
| IPO Year | N/A | 2013 |
| Metric | ADSE | ESPR |
|---|---|---|
| Price | $11.40 | $3.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 2.5K | ★ 8.7M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | $549.86 | N/A |
| Revenue Next Year | N/A | $12.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $7.89 | $0.95 |
| 52 Week High | $13.90 | $4.18 |
| Indicator | ADSE | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 70.72 |
| Support Level | $11.20 | $3.11 |
| Resistance Level | $12.01 | $3.18 |
| Average True Range (ATR) | 0.40 | 0.01 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 62.28 | 77.78 |
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. The company generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.